Keytruda

News

NICE backs use of MSD's KEYTRUDA for triple-negative breast ...

For the first time, patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy at an earlier stage of their treatment journey, as Merck & Co/MSD'

News

Scotland backs three new uses for MSD's Keytruda

Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD's Keytruda in combination with Eisai's Lenvima as a treatment for advanced or recurrent

News

Routine NHS access to Ibrance assured with new NICE guidance

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui

News

Opdivo set to take on Keytruda in adjuvant melanoma

Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient dea

News

Keytruda fluffs its lines in prostate, liver cancer trials

Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer imm

Oncology